Articles: 162
(average impact: 4.6); Book chapters: 19: Citations:
6313 (by May 2023).
(Last update: May 2024, click here
for full list).
Selected Articles Five selected articles from the last 2 years (average impact: 5.45).
Zamora M, Harris D, Davies N, Ebnet J, Radermacher P, Brucker C, Waller C, Robles JP, Bertsch T, Clapp C, Triebel J. Immunometric and functional measurement of endogenous vasoinhibin in human sera. Frontiers in Endocrinology, 2024. doi: 10.3389/fendo.2024.1345996. FI: 6.055
Núñez-Amaro CD, López M, Adán-Castro E, Robles-Osorio ML, García-Franco L, García-Roa M, Villalpando-Robles Y, Ramírez-Neria P, Pineiro N, Rubio-Mijangos JF, Sánchez J, Ramírez-Hernández G, Siqueiros-Márquez L, Díaz-Lezama N, López-Star E, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. Levosulpiride for the treatment of diabetic macular oedema: A phase 2 randomized clinical trial. EYE, 2023. doi: 10.1038/s41433-023-02715-5. FI: 4.456
Robles JP, Zamora M, Garcia-Rodrigo JF, Perez AL, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. The apoptotic inflammatory, and fibrinolytic actions of vasoinhibin are in a motif different from its antiangiogenic HGR motif. Endocrinology 165:1-12, 2024. https://doi.org/10.1210/endocr/bqad185. FI: 5.045
García-Rodrigo JF, Ortíz-Arballo G, Martínez-Díaz OF, Furuzawa-Carballeda J, Ruíz-Herrera X, Macías F, Ledesma-Colunga MG, Martínez de la Escalera G, Clapp C. Prolactin inhibits or stimulates the inflammatory response of joint tissues in a cytokine-dependent manner. Endocrinology 164:1-14, https://doi.org/10.1210/endocr/bqad156, 2023. FI: 5.045
Robles JP, Zamora M, Siqueiros-Marquez L, Adan-Castro E, Ramirez-Hernadez G, Nuñez FF, Lopez-Casillas F, Millar RP, Bertsch T, Martínez de la Escalera G, Tiebel J, Clapp C. The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide. Angiogenesis 25:57-70, 2022. Doi: 10.1007/s10456-021-09800-x. FI: 9.78
